Structure-based design of potent and selective inhibitors of the HECT ligase NEDD4.
Maspero E, Cappa A, Weber J, Trifirò P, Amici R, Bruno A, Fagà G, Cecatiello V, Fattori R, Leuzzi B, Taibi V, Meroni G, Pasi M, Romussi A, Sartori L, Villa M, Vultaggio S, Cirò M, Soffientini P, Lombardo L, Dahe S, Bachi A, Varasi M, Rossi M, Pasqualato S, Mercurio C, Polo S.
Maspero E, et al.
Commun Chem. 2025 May 28;8(1):164. doi: 10.1038/s42004-025-01557-4.
Commun Chem. 2025.
PMID: 40437006
Free PMC article.
Among these, compound 32 emerged as a potent lead (IC(50) = 0.12 M) with favorable pharmacokinetic properties, including oral bioavailability, paving the way for future in vivo efficacy studies....
Among these, compound 32 emerged as a potent lead (IC(50) = 0.12 M) with favorable pharmacokinetic properties, including oral bioavai …